Introduction
The management of patients who are receiving anticoagulants and require surgery or an invasive procedure is a common clinical problem that, paradoxically, is both trivial and complex 1, 2 . It is trivial because stopping and resuming an anticoagulant is simple enough: wait until the anticoagulant effect wears off and resume it when there is adequate hemostasis. It is complex because of the wide range of perceived thromboembolic risks during anticoagulant interruption. Consider that in a prospective cohort study assessing warfarin interruption in 535 low-to-moderate risk patients with atrial fibrillation who interrupted warfarin and did not receiving heparin bridging, the incidence of arterial thromboembolism was 0.7% (95% confidence interval [CI]: 0.2-1.9) 3 . The authors concluded that, '…for many patients receiving warfarin who need a minor procedure, a
brief (5 day) interruption of therapy is associated with a low risk of thromboembolism'.
Now consider a retrospective cohort study which estimated a risk for thrombotic events of 1 per 6,219 (0.016%) during warfarin interruption in a broad spectrum of warfarintreated patients 4 .
The authors concluded that, 'with no documented increase in severe
For personal use only. on November 12, 2017 . by guest www.bloodjournal.org From bleeding during perioperative continuation of warfarin, these data provide a compelling argument to maintain patients on warfarin during cutaneous operations'. Thus, one group felt a risk for thromboembolism of 0.7% associated with simply stopping and restaring warfarin was acceptable, obviating the need for heparin bridging, whereas another group thought a risk of 0.016% was too high and justified perioperative continuation of warfarin. Added to these varied perceptions of thromboembolic risk is the wide range of surgical and other invasive procedures patients undergo and clinicians' differing perceptions of associated bleeding risk 5, 6 . Overall, the perceived risk for thromboembolism will likely drive patient management 6 , and if it is perceived to be greater than the risk for bleeding this will determine if heparin bridging is administered during warfarin interruption.
Caught in between these varied, and at times extreme, perceptions of risks to patients is the practicing clinician who seeks an evidence-based approach to patient management. Addressing this need is problematic as high-quality evidence from randomized trials of perioperative anticoagulation is lacking 7 . In an attempt to bridge this disparity between clinical need and limited evidence, the approach herein aims to update the best available evidence on perioperative anticoagulant management, using the GRADE working group's approach to evidence appraisal 8 , and is framed on the following key clinical questions:
• How to stratify patients according to risk for thromboembolism and bleeding?
• When is perioperative interruption of warfarin therapy not required?
• If warfarin interruption is required, when should it be stopped and resumed?
• If warfarin therapy is stopped, when is heparin bridging required?
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• How should heparin bridging be given before and after surgery, and at what dose?
In the practice recommendations mentioned herein, attention should be given to the wording. In accordance with the GRADE system, a recommendation statement with the wording "clinicians should" reflects a strong recommendation, which may be applied to most patients. A statement with the wording "clinicians may consider" reflects a weak recommendation, which would be applied to many patients but may not be applied to many other patients; in such circumstances, clinicians should consider individual patient characteristics and patients' values and preferences to decide on the treatment and/or management course taken.
How to stratify patients according to risk for thromboembolism and bleeding?
There are no validated risk stratification schemes to estimate risk for perioperative stroke or thromboembolism as is the case with the CHADS 2 and CHA 2 DS 2 VASc prediction guides, which are used in a non-perioperative clinical setting 9, 10 . The suggested risk stratification scheme in Table 1 is an empiric formulation derived largely from indirect evidence of risk in a non-perioperative setting. In patients with atrial fibrillation, additional evidence from a large, linked administrative database that gathered data from 1996 to 2001 (during a pre-bridging era) suggests that the CHADS 2 score may estimate postoperative risk for stroke ( Table 2) 11 . The 30-day postoperative incidence of stroke appeared higher than that expected based on the annual risk if pro-rated over a 30-day period, in turn supporting the premise that the perioperative milieu is prothrombotic 12 . There is also emerging data that the type of surgery influences the risk for stroke, as is already established for cardiac bypass and carotid endarterectomy 11, 13, 14 . • coronary artery bypass, heart valve replacement, intracranial or intraspinal surgery, in which surgical site bleeding can have serious consequences
• major vascular surgery such as aortic aneurysm repair and peripheral artery bypass, in which extensive vascular tissue damage predisposes to bleeding
• major orthopedic, reconstructive plastic and major cancer surgery, in which the extent of tissue injury predisposes to bleeding
• urogenital surgery (prostate and bladder resection), in which endogenous urokinase promotes bleeding
There are also more minor procedures that confer an increased risk for bleeding 7 :
• colon polypectomy, in which the polyp stalk transection site (especially if >1 cm diameter) may have ongoing bleeding that worsens with re-anticoagulation 
When is perioperative interruption of warfarin therapy not required?
In general, interruption of warfarin is not required for minor dental, skin and eye procedures consisting of tooth extractions or endodontic (root canal) procedures, small skin excisions (basal and squamous cell skin cancers, actinic keratoses, and premalignant or cancerous skin nevi), and cataract removal 7 .
Randomized trials and prospective cohort studies have assessed continuing warfarin around dental procedures 7, 16 , and several management strategies that have been assessed: i) continuing warfarin ±co-administered prohemostatic interventions (antifibrinolytic drugs and/or sutures); ii) partial (2-3 day before procedure) warfarin interruption; and iii) complete (5-6 day before procedure) warfarin interruption. In trials that compared different strategies, continuing warfarin with a prohemostatic agent (5 mL oral tranexamic acid, 5-10 minutes before and 3-4 times daily for 1-2 days after procedure) conferred a low risk for bleeding. Another approach associated with a low risk for bleeding is partial interruption of warfarin for 2-3 days before the dental procedure.
For skin procedures, prospective cohort studies reported a 3-fold higher incidence of minor bleeding in patients who continued warfarin compared with patients who had warfarin interruption, but most bleeds were self-limiting 17, 18 .
For cataract removal, a common surgery among elderly warfarin-treated patients, the incidence of clinically important bleeding with continued warfarin appears low, reflecting that it is a largely avascular procedure. Thus, in a meta-analysis of warfarintreated patients having cataract surgery, patients who continued warfarin had a 3-fold increased risk for minor bleeding (odds ratio [OR]; 3.26; CI: 1.73-6.16), with an overall incidence of bleeding of 10%, but almost all bleeds were self-limiting dot hyphemae or Nonetheless, if there is concern about retrobulbar hemorrhage a discussion between the internist and ophthalmologist may be warranted to discuss management options, including perioperative interruption of warfarin or continuation with the cataract extraction being done using a phacoemulsification approach and topical anesthesia. 
If warfarin interruption is required, when should it be stopped and resumed?
The current recommendation to stop warfarin 5 days before surgery, intended to provide normal or near-normal hemostasis at surgery, is based on three data sources. The first relates to the pharmacodynamic properties of warfarin, namely the synthesis rate of functional coagulation factors II and X after warfarin interruption. Assuming first-order 
If warfarin therapy is stopped, when is heparin bridging required?
The need for heparin bridging during warfarin interruption is driven largely by patients' estimated risk for perioperative thromboembolism which, in turn, is determined by the indication for warfarin and, to a lesser extent, by the type of surgery. Ideally, randomized trials which allocate patients to a heparin bridging or no bridging strategy should be used to determine best perioperative anticoagulation practices, and such trials are in progress 2 . A suggested approach for heparin bridging is provided in Table 3 .
Among patients classified as 'high-risk', observational studies have assessed heparin bridging typically with a therapeutic-dose low-molecular-weight heparin (LMWH) regimen such as enoxaparin 1 mg/kg SC twice-daily. Such heparin bridging regimens are associated with a 1-2% incidence of thromboembolism and a 2-4% incidence of major bleeding, the later typically defined as bleeding associated with a symptomatic >2g/dL decrease in hemoglobin or need for transfusion of two or more units of packed red blood cells 7 . Heparin bridging with intravenous unfractionated heparin (UFH) has also been studied in such patients, with rates of thromboembolism and bleeding comparable to that of LMWH bridging 26 , but it is infrequently used 7 .
Among 'moderate-risk' patients, observational studies have assessed different bridging regimens, including therapeutic-dose LMWH, intermediate-dose LMWH (e.g., enoxaparin, 40 mg SC twice-daily) and, in a minority of patients, no heparin bridging.
Irrespective of the anticoagulation strategy used, the incidence of thromboembolic events was ~1% 27 . Given the uncertainty about which patients can be managed with a bridging or no bridging strategy, the decision about perioperative anticoagulation should be based on individual patient-and surgery-related factors. Patients groups within this risk stratum in whom bridging may be considered include those with:
• prior stroke or systemic embolism 3, 27, 28 . given on the evening before surgery 29, 30 . Thus, on the day before surgery patients should receive only the morning dose if a twice-daily LWMH regimen is used or 50% of the total dose if a once-daily LWMH regimen is used.
Recommendations
After surgery, assessing the risk for bleeding depends on the anticipated surgeryspecific risk and the evaluation of wound hemostasis. Consequently, the assessment of bleeding risk, which drives the decision about when (and if) to resume heparin bridging in the postoperative period, is largely subjective and individualized. The judicious resumption of anticoagulants postoperatively is critical to prevent serious bleeding. Three factors may be considered to minimize postoperative bleeding:
• Time interval since surgery. No trials have compared an early (within 24 hours after surgery) or late (more than 24 hours after surgery) resumption of therapeutic-dose LMWH bridging after surgery. In a prospective cohort study in which all patients received enoxaparin, 1.5 mg/kg, at a fixed time period, 12-24 hours after surgery, the incidence of major bleeding was 20% (8 of 40) after major surgery and 0.7% (1 of 148) after minor surgery 31 . Other studies that allowed a flexible postoperative bridging regimen in high-bleeding risk patients, with either delayed resumption of therapeutic-dose LMWH or substitution of a low-dose regimen, found a low incidence of major bleeding (<5%) 24, 25 . Overall, these findings suggest that when resuming therapeutic-dose LMWH, it should be delayed for at least 24 hours and probably longer (48-72 hours) in patients having major surgery. In patients having minor surgery who received therapeutic-dose LMWH bridging started ~24 hours (on the morning of the day after surgery), the incidence of major and non-major bleeding was <5%.
• Heparin dose when bridging is resumed. Therapeutic-dose LMWH (and UFH) have been shown to be associated with a higher risk of major bleeding compared to low-dose LMWH or UFH regimen or no bridging (OR 4.4; 95% CI: 1.5-14.7)
in a prospective multicenter registry 5 .
• Flexibility in postoperative resumption of anticoagulant therapy. Several studies demonstrate a low (1-3%) risk for major bleeding after major surgery if the timing 
